BidaskClub upgraded shares of EXACT Sciences (NASDAQ:EXAS) from a hold rating to a buy rating in a research note issued to investors on Thursday.
Several other analysts have also recently issued reports on the company. Zacks Investment Research cut EXACT Sciences from a hold rating to a sell rating in a report on Wednesday, February 28th. Robert W. Baird upgraded EXACT Sciences from a neutral rating to an outperform rating and increased their price target for the stock from $42.56 to $56.00 in a report on Tuesday, February 27th. Leerink Swann set a $67.00 price target on EXACT Sciences and gave the stock a buy rating in a report on Friday, February 23rd. Benchmark cut EXACT Sciences from a buy rating to a hold rating in a report on Friday, February 23rd. Finally, Goldman Sachs Group assumed coverage on EXACT Sciences in a report on Monday, January 29th. They set a neutral rating and a $51.00 price target for the company. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. EXACT Sciences presently has a consensus rating of Buy and a consensus price target of $52.84.
Shares of EXACT Sciences (NASDAQ:EXAS) opened at $52.15 on Thursday. The company has a quick ratio of 6.77, a current ratio of 7.15 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $6,307.10, a price-to-earnings ratio of -52.15 and a beta of 0.71. EXACT Sciences has a twelve month low of $19.91 and a twelve month high of $63.60.
In related news, insider Graham Peter Lidgard sold 39,884 shares of the stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $43.10, for a total transaction of $1,719,000.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Kevin T. Conroy sold 125,402 shares of the stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $52.79, for a total value of $6,619,971.58. Following the transaction, the insider now directly owns 955,454 shares in the company, valued at approximately $50,438,416.66. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 547,463 shares of company stock valued at $27,045,199. Company insiders own 4.00% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. C M Bidwell & Associates Ltd. acquired a new position in EXACT Sciences during the 4th quarter worth about $117,000. Crow Point Partners LLC acquired a new position in EXACT Sciences during the 4th quarter worth about $145,000. Oppenheimer Asset Management Inc. lifted its stake in EXACT Sciences by 2,925.7% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock worth $150,000 after acquiring an additional 3,072 shares in the last quarter. Advisory Services Network LLC lifted its stake in EXACT Sciences by 6,600.0% during the 4th quarter. Advisory Services Network LLC now owns 3,350 shares of the medical research company’s stock worth $176,000 after acquiring an additional 3,300 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in EXACT Sciences during the 3rd quarter worth about $183,000. 82.05% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3257285/exact-sciences-exas-lifted-to-buy-at-bidaskclub.html.
About EXACT Sciences
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.